PDF(Pubmed)
Abstract：
UNASSIGNED: This study focuses on assessing the cost-effectiveness of incorporating toripalimab alongside chemotherapy for the treatment of patients diagnosed with metastatic triple-negative breast cancer from the perspective of the Chinese healthcare system.
UNASSIGNED: A partitioned survival model was constructed to simulate the costs and health outcomes over the lifetime of patients with mTNBC. Clinical data regarding overall survival, progression-free survival, and treatment-related adverse events were derived from the TORCHLIGHT clinical trials. Incremental cost-effectiveness ratio (ICER) were calculated based on the gains in quality-adjusted life-year (QALY). The willingness-to-pay (WTP) threshold was defined as $39,855.79 per QALY. Additionally, sensitivity analyses were conducted to examine the robustness of the model.
UNASSIGNED: The total cost incurred by the group receiving toripalimab was $38,040.62, while the placebo plus chemotherapy was $26,102.07. The utilization of the toripalimab regimen resulted in an increase of 0.74 QALYs and an incremental cost of $11,938.55 compared to the placebo plus chemotherapy group. The ICER was $16,133.18/QALY, indicating that toripalimab plus chemotherapy is a cost-effective strategy according to the WTP threshold. Sensitivity analyses confirmed the robustness of the results.
UNASSIGNED: This study suggests that the addition of toripalimab to chemotherapy for the treatment of mTNBC is a cost-effective strategy. The findings provide valuable evidence to guide decision-making regarding treatment selection for patients with mTNBC in China.
UNASSIGNED: A partitioned survival model was constructed to simulate the costs and health outcomes over the lifetime of patients with mTNBC. Clinical data regarding overall survival, progression-free survival, and treatment-related adverse events were derived from the TORCHLIGHT clinical trials. Incremental cost-effectiveness ratio (ICER) were calculated based on the gains in quality-adjusted life-year (QALY). The willingness-to-pay (WTP) threshold was defined as $39,855.79 per QALY. Additionally, sensitivity analyses were conducted to examine the robustness of the model.
UNASSIGNED: The total cost incurred by the group receiving toripalimab was $38,040.62, while the placebo plus chemotherapy was $26,102.07. The utilization of the toripalimab regimen resulted in an increase of 0.74 QALYs and an incremental cost of $11,938.55 compared to the placebo plus chemotherapy group. The ICER was $16,133.18/QALY, indicating that toripalimab plus chemotherapy is a cost-effective strategy according to the WTP threshold. Sensitivity analyses confirmed the robustness of the results.
UNASSIGNED: This study suggests that the addition of toripalimab to chemotherapy for the treatment of mTNBC is a cost-effective strategy. The findings provide valuable evidence to guide decision-making regarding treatment selection for patients with mTNBC in China.
摘要：
■这项研究的重点是从中国医疗保健系统的角度评估合并toripalimab和化疗治疗转移性三阴性乳腺癌患者的成本效益。
■构建分区生存模型以模拟mTNBC患者一生中的成本和健康结果。关于总生存率的临床数据，无进展生存期,与治疗相关的不良事件来自TORCHLIGHT临床试验.增量成本效益比（ICER）是根据质量调整生命年（QALY）的收益计算的。支付意愿(WTP)门槛定义为每QALY39,855.79美元。此外,进行了敏感性分析，以检验模型的稳健性。
■接受toripalimab的组的总费用为38,040.62美元，而安慰剂加化疗为26,102.07美元。与安慰剂加化疗组相比，toripalimab方案的使用导致了0.74QALY的增加和11,938.55美元的增加成本。ICER为$16,133.18/QALY，表明根据WTP阈值，托里帕利马联合化疗是一种具有成本效益的策略。敏感性分析证实了结果的稳健性。
■这项研究表明，在mTNBC的化疗中添加托里帕利马单抗是一种具有成本效益的策略。研究结果为指导中国mTNBC患者的治疗选择提供了有价值的证据。
■构建分区生存模型以模拟mTNBC患者一生中的成本和健康结果。关于总生存率的临床数据，无进展生存期,与治疗相关的不良事件来自TORCHLIGHT临床试验.增量成本效益比（ICER）是根据质量调整生命年（QALY）的收益计算的。支付意愿(WTP)门槛定义为每QALY39,855.79美元。此外,进行了敏感性分析，以检验模型的稳健性。
■接受toripalimab的组的总费用为38,040.62美元，而安慰剂加化疗为26,102.07美元。与安慰剂加化疗组相比，toripalimab方案的使用导致了0.74QALY的增加和11,938.55美元的增加成本。ICER为$16,133.18/QALY，表明根据WTP阈值，托里帕利马联合化疗是一种具有成本效益的策略。敏感性分析证实了结果的稳健性。
■这项研究表明，在mTNBC的化疗中添加托里帕利马单抗是一种具有成本效益的策略。研究结果为指导中国mTNBC患者的治疗选择提供了有价值的证据。
